Castleark Management LLC lowered its position in Guardant Health, Inc. (NASDAQ:GH – Free Report) by 2.9% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 160,283 shares of the company’s stock after selling 4,760 shares during the quarter. Castleark Management LLC owned 0.12% of Guardant Health worth $14,805,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its holdings in Guardant Health by 2.1% in the 4th quarter. Vanguard Group Inc. now owns 12,160,768 shares of the company’s stock valued at $1,242,101,000 after purchasing an additional 251,939 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its stake in shares of Guardant Health by 33.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,636,078 shares of the company’s stock worth $575,670,000 after purchasing an additional 1,414,441 shares in the last quarter. Franklin Resources Inc. lifted its stake in shares of Guardant Health by 14.9% during the fourth quarter. Franklin Resources Inc. now owns 3,361,547 shares of the company’s stock worth $343,348,000 after purchasing an additional 435,232 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Guardant Health by 9.4% in the fourth quarter. Geode Capital Management LLC now owns 3,213,657 shares of the company’s stock worth $328,297,000 after buying an additional 277,001 shares during the period. Finally, Fuller & Thaler Asset Management Inc. boosted its position in shares of Guardant Health by 3.0% in the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 2,441,730 shares of the company’s stock worth $249,398,000 after buying an additional 72,162 shares during the period. Hedge funds and other institutional investors own 92.60% of the company’s stock.
Guardant Health Stock Performance
GH stock opened at $147.33 on Monday. Guardant Health, Inc. has a twelve month low of $40.35 and a twelve month high of $174.08. The company has a market capitalization of $19.54 billion, a P/E ratio of -43.46 and a beta of 1.59. The firm has a 50 day simple moving average of $139.41 and a 200-day simple moving average of $112.02.
Wall Street Analysts Forecast Growth
Read Our Latest Stock Analysis on GH
Insider Transactions at Guardant Health
In other news, CFO Michael Brian Bell sold 2,000 shares of the business’s stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $128.62, for a total value of $257,240.00. Following the completion of the sale, the chief financial officer owned 47,509 shares of the company’s stock, valued at approximately $6,110,607.58. The trade was a 4.04% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Myrtle S. Potter sold 1,556 shares of the company’s stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $131.16, for a total transaction of $204,084.96. Following the completion of the sale, the director owned 20,971 shares in the company, valued at approximately $2,750,556.36. This trade represents a 6.91% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 708,565 shares of company stock valued at $90,556,597 over the last ninety days. 5.60% of the stock is currently owned by corporate insiders.
About Guardant Health
Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.
The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.
Read More
- Five stocks we like better than Guardant Health
- RTX and Lockheed Earnings: Can Strong Guidance Reset the Defense Trade?
- These 4 Earnings Reports Expose the Market’s Growing Economic Divide
- Broadcom May Be the Biggest Winner From Alphabet’s Earnings
- Volatility Is Back and These 3 Market Tollbooths Are Best Positioned to Profit
Want to see what other hedge funds are holding GH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Guardant Health, Inc. (NASDAQ:GH – Free Report).
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.
